Hepatitis E infection with a benign course during vedolizumab treatment for Crohn's disease: A case report: Hepatitis E during vedolizumab therapy in IBD
We present a 49 year old female patient with Crohn's disease (CD) in remission on vedolizumab therapy who experienced a symptomatic, though benign, course of acute hepatitis E. Routine blood tests showed substantial elevation of liver enzymes and polymerase chain reaction (PCR) testing confirme...
Main Authors: | de Man, R.A (Author), de Vries, A.C (Author), Goetgebuer, R.L (Author), Masclee, G.M.C (Author), van der Eijk, A.A (Author), van der Woude, C.J (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier Masson s.r.l.
2022
|
Subjects: | |
Online Access: | View Fulltext in Publisher |
Similar Items
-
Predicting Response to Vedolizumab in Inflammatory Bowel Disease
by: Joseph Meserve, et al.
Published: (2020-04-01) -
Crohn’s Disease with Atypical Extra-Intestinal Manifestations Developing Under Treatment with Vedolizumab
by: Aasem Abu Shtaya, et al.
Published: (2021-02-01) -
Selective biologics for ulcerative colitis and Crohn's disease – clinical utility of vedolizumab
by: Petkau JM, et al.
Published: (2016-03-01) -
Vedolizumab in Inflammatory Bowel Disease: West versus East
by: Prasanta Debnath, et al.
Published: (2021-01-01) -
Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study
by: Rupa Banerjee, et al.
Published: (2021-01-01)